Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer

European Journal of Gynaecological Oncology

Volumn 35, Issue 3, 2014, Pages 224-229

  Matoda, M ^a   Omatsu, K ^a   Yamamoto, A ^a   Nomura, H ^a   Tanigawa, T ^a   Kawamata, Y ^a   Kato, K ^a   Umayahara, K ^a   Takeshima, N ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Advanced and recurrent endometrial cancer; Platinum free interval; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IRINOTECAN; NEDAPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOSARCOMA; CLINICAL EFFECTIVENESS; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE CARE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84902525818     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgo24392014     Document Type: Article

References (18)

1. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E, Carson L.F., Evers C.: "A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study". J. Clin. Oncol., 1994,12, 1408.
2. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A. et al.: "Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study". J. Clin. Oncol. 2004, 22, 3902.
3. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L. et al.: "Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study". Ann. Oncol. 2004, 75, 1173.
4. Fleming G.F., Brunetto V.L., Celia D., Look K.Y., Reid G.C., Munkarah A.R. et al.: "Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study". J. Clin. Oncol. 2004, 22, 2159.
5. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oncol. 1991, 9, 389.
6. Moore K.N., Tian C., McMeekin D.S., Thigpen J.T., Randall M.E., Gallion H.H.: "Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A Gynecologic Oncology Group ancillary data analysis". Cancer, 2010, 116, 5407.
7. Rose P.G., Blessing J.A., Lewandowski G.A., Creasman W.T., Webster K.D.: "A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study". Gynecol. Oncol., 1996, 63, 101.
8. Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F.: "Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study". Gynecol. Oncol., 2003, 88, 277.
9. Moore D.H., Blessing J.A., Dunton C., Buller R.E., Reid G.C.: "Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group". Gynecol. Oncol., 1999, 75, 473.
10. Muggia F.M., Blessing J.A., Sorosky J., Reid G.C.: "Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2002, 20, 2360.
11. Plaxe S., Blessing J.A., Husseindazeh N., Webster K.D., Rader J.S., Dunton C.J.: "Phase II trial of pyrazoloacridine in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study". Gynecol. Oncol., 2002, 84, 241.
12. Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E.: "A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study". Gynecol. Oncol., 2002, 87, 247.
13. Fracasso P.M., Blessing J.A., Molpus K.L., Adler L.M., Sorosky J.I., Rose P.G.: "Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study". Gynecol. Oncol., 2006, 103, 523.
14. Schilder R., Blessing J.A., Pearl M.L., Rose P.G.: "Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group". Invest. New Drugs, 2004, 22, 343.
15. Grendys E.C. Jr., Blessing J.A., Burger R., Hoffman J.: "A phase II evaluation of flavorpiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study". Gynecol. Oncol., 2005, 98, 249.
16. Aghajanian C., Sill M.W., Dancy K.M., Greer B., McMeekin D.S., Rose P.G. et al.: "Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2011, 29, 2259.
17. Oza A.M., Elit L., Tsao M.S., Kamel-Reid S., Biagi J., Provencher D.M. et al.: "Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group". J. Clin. Oncol., 2001, 29, 3278.
18. Alvarez E.A., Brady W.E., Walker J.L., Rotmensch J., Zhou X.C., Kendrick J.E. et al.: "Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study". Gynecol. Oncol., 2013, 129, 22. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20.